From the Division of Infectious Diseases, The Ohio State University College of Medicine.
Division of General Internal Medicine.
Sex Transm Dis. 2022 Jan 1;49(1):50-54. doi: 10.1097/OLQ.0000000000001496.
Sexually transmitted infections (STIs) are a common reason for evaluation in the emergency department (ED). Given the overlapping risk factors for STIs, patients screened for gonorrhea and chlamydia should be tested for syphilis and HIV. Syphilis and HIV testing rates in the ED have been reported to be low. The study objective was to examine whether collaboration between emergency medicine (EM) and infectious disease (ID) providers improved syphilis and HIV testing in the ED.
A multidisciplinary team of EM and ID providers was formed to identify and address barriers to syphilis and HIV testing in the ED. Syphilis, HIV, chlamydia, and gonorrhea testing and infection rates were calculated and compared during 2 time periods: preintervention (January 1, 2012-December 30, 2017) and postintervention (November 1, 2018-November 30, 2019). We also extracted clinical and laboratory data from patients with positive syphilis and HIV results during the study period.
The most commonly cited barrier to syphilis and HIV testing was concern about follow-up of positive results. Compared with the preintervention period, syphilis and HIV testing rates increased significantly in the postintervention period (incidence rate ratios, 30.70 [P < 0.0001] and 28.99 [P < 0.0001] for syphilis and HIV, respectively). The postintervention period was also associated with a significant increase in the identification of patients with positive syphilis and HIV results (incidence rate ratios, 7.02 [P < 0.0001] and 2.34 [P = 0.03], respectively).
Collaboration between EM and ID providers resulted in a significant increase in syphilis and HIV testing and diagnosis in the ED.
性传播感染(STIs)是急诊科(ED)评估的常见原因。鉴于 STIs 的重叠风险因素,筛查淋病和衣原体的患者应接受梅毒和 HIV 检测。据报道,ED 中的梅毒和 HIV 检测率较低。本研究的目的是检查急诊医学(EM)和传染病(ID)提供者之间的合作是否改善了 ED 中的梅毒和 HIV 检测。
成立了一个由 EM 和 ID 提供者组成的多学科团队,以确定和解决 ED 中梅毒和 HIV 检测的障碍。在两个时间段计算和比较了梅毒、HIV、衣原体和淋病检测和感染率:干预前(2012 年 1 月 1 日至 2017 年 12 月 30 日)和干预后(2018 年 11 月 1 日至 2019 年 11 月 30 日)。我们还从研究期间阳性梅毒和 HIV 结果的患者中提取了临床和实验室数据。
梅毒和 HIV 检测最常被引用的障碍是对阳性结果的后续关注。与干预前时期相比,干预后时期梅毒和 HIV 检测率显著增加(发病率比,30.70[P <0.0001]和 28.99[P <0.0001],分别为梅毒和 HIV)。干预后时期也与识别出患有阳性梅毒和 HIV 结果的患者数量显著增加相关(发病率比,7.02[P <0.0001]和 2.34[P = 0.03],分别为梅毒和 HIV)。
EM 和 ID 提供者之间的合作导致 ED 中梅毒和 HIV 检测和诊断显著增加。